Esperion Therapeutics (ESPR) Trading Down 5.7%
Esperion Therapeutics Inc (NASDAQ:ESPR) traded down 5.7% on Friday . The stock traded as low as $43.00 and last traded at $43.16. 1,551,030 shares were traded during mid-day trading, an increase of 78% from the average session volume of 873,123 shares. The stock had previously closed at $45.75.
Several equities research analysts have recently weighed in on the company. BidaskClub downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 12th. ValuEngine cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, June 21st. Zacks Investment Research upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $48.00 price target on the stock in a research note on Tuesday, July 31st. Chardan Capital upgraded Esperion Therapeutics to a “hold” rating and set a $32.50 price target on the stock in a research note on Friday, July 20th. Finally, Stifel Nicolaus started coverage on Esperion Therapeutics in a research note on Friday, September 14th. They issued a “buy” rating and a $89.00 price target on the stock. Three analysts have rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $80.58.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.70) by ($0.01). During the same period last year, the business posted ($1.92) earnings per share. sell-side analysts expect that Esperion Therapeutics Inc will post -6.31 earnings per share for the current fiscal year.
Several institutional investors have recently made changes to their positions in the company. Northern Trust Corp raised its position in shares of Esperion Therapeutics by 1.8% during the 2nd quarter. Northern Trust Corp now owns 590,104 shares of the biopharmaceutical company’s stock worth $23,126,000 after purchasing an additional 10,702 shares during the period. Bank of Nova Scotia acquired a new stake in shares of Esperion Therapeutics during the 2nd quarter worth approximately $13,325,000. Granahan Investment Management Inc. MA acquired a new stake in shares of Esperion Therapeutics during the 2nd quarter worth approximately $4,207,000. Nexthera Capital LP acquired a new stake in shares of Esperion Therapeutics during the 2nd quarter worth approximately $11,259,000. Finally, Partner Fund Management L.P. raised its position in shares of Esperion Therapeutics by 117.7% during the 2nd quarter. Partner Fund Management L.P. now owns 2,460,157 shares of the biopharmaceutical company’s stock worth $96,414,000 after purchasing an additional 1,330,159 shares during the period.
About Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Featured Story: What is a Call Option?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.